Press "Enter" to skip to content

China’s Junshi Biosciences raises $394 mln after pricing IPO at bottom of range

The firm aims to take advantage of rules introduced by Hong Kong’s stock exchange in April allowing listings from pre-revenue biotechs, as the bourse competes to attract startups.

Original source: https://health.economictimes.indiatimes.com/news/pharma/chinas-junshi-biosciences-raises-394-mln-after-pricing-ipo-at-bottom-of-range/67127690?utm_source=RSS&utm_medium=ETRSS

Also Read:   AstraZeneca moves US court against Dr Reddy's on generic drug Brilinta